Current Report Filing (8-k)
July 07 2022 - 6:03AM
Edgar (US Regulatory)
0001442999
false
0001442999
2022-07-06
2022-07-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 6, 2022
Alterola Biotech, Inc.
(Exact name of registrant as specified in its charter)
| Nevada |
333-156091 |
82-1317032 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
47 Hamilton Square Birkenhead Merseyside United
Kingdom |
CH41 5AR |
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: +44 151 601
9477
|
________________________________________________
(Former name or former address, if changed since last
report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] |
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| |
|
| [ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| [ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| [ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. [ ]
SECTION 8 – Other Events
On July 6, 2022, we issued a press release announcing our internal
investigation into certain transactions involving illegitimate share transactions / holdings of our securities and our efforts to
place stop orders on these shares with our transfer agent. A copy of the press release is attached as Exhibit 99.1 to this Current
Report on Form 8-K.
The information in Item 8.01 of this Current Report
on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in
such a filing.
SECTION 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits |
99.1 Press release, dated July 6, 2022
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Alterola Biotech, Inc.
/s/ Seamus McAuley
Seamus McAuley
Chief Executive Officer
Date: July 6, 2022
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Jan 2024 to Jan 2025
